EE423 Cost-Effectiveness of Vaccinating Adults ≥65 Years and at-Risk Individuals 18-64 Years With the 20-Valent Pneumococcal Conjugate Vaccine Versus Currently Recommended Vaccine Regimens in Sweden

Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.669
https://www.valueinhealthjournal.com/article/S1098-3015(22)02873-X/fulltext
Section Title :
Section Order : 10201
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02873-X&doi=10.1016/j.jval.2022.09.669
HEOR Topics :
Tags :
Regions :